Labcorp (LH) Competitors

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

In the previous week, Medpace had 6 more articles in the media than Labcorp. MarketBeat recorded 11 mentions for Medpace and 5 mentions for Labcorp. Medpace's average media sentiment score of 0.85 beat Labcorp's score of 0.58 indicating that Medpace is being referred to more favorably in the media.

78.0% of Medpace shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Medpace has a net margin of 17.67% compared to Labcorp's net margin of 6.99%. Medpace's return on equity of 110.15% beat Labcorp's return on equity.

Medpace currently has a consensus target price of $595.20, suggesting a potential downside of 2.80%. Labcorp has a consensus target price of $336.36, suggesting a potential upside of 5.01%. Given Labcorp's stronger consensus rating and higher probable upside, analysts clearly believe Labcorp is more favorable than Medpace.

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market. Comparatively, Labcorp has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Labcorp has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

In the previous week, AMN Healthcare Services had 4 more articles in the media than Labcorp. MarketBeat recorded 9 mentions for AMN Healthcare Services and 5 mentions for Labcorp. Labcorp's average media sentiment score of 0.58 beat AMN Healthcare Services' score of 0.55 indicating that Labcorp is being referred to more favorably in the media.

Labcorp presently has a consensus price target of $336.36, suggesting a potential upside of 5.01%. AMN Healthcare Services has a consensus price target of $36.00, suggesting a potential upside of 5.53%. Given AMN Healthcare Services' higher possible upside, analysts plainly believe AMN Healthcare Services is more favorable than Labcorp.

Labcorp has a net margin of 6.99% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Labcorp's return on equity.

Labcorp has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.38, meaning that its share price is 62% less volatile than the broader market.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 1.1% of AMN Healthcare Services shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Labcorp currently has a consensus price target of $336.36, suggesting a potential upside of 5.01%. Bio-Rad Laboratories has a consensus price target of $343.33, suggesting a potential downside of 8.56%. Given Labcorp's stronger consensus rating and higher possible upside, equities analysts clearly believe Labcorp is more favorable than Bio-Rad Laboratories.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Labcorp has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, Labcorp had 3 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 5 mentions for Labcorp and 2 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.63 beat Labcorp's score of 0.58 indicating that Bio-Rad Laboratories is being referred to more favorably in the news media.

Bio-Rad Laboratories has a net margin of 8.59% compared to Labcorp's net margin of 6.99%. Labcorp's return on equity of 16.74% beat Bio-Rad Laboratories' return on equity.

Cardinal Health currently has a consensus target price of $266.56, indicating a potential upside of 18.50%. Labcorp has a consensus target price of $336.36, indicating a potential upside of 5.01%. Given Cardinal Health's stronger consensus rating and higher possible upside, analysts plainly believe Cardinal Health is more favorable than Labcorp.

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Cardinal Health has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Labcorp has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

In the previous week, Cardinal Health had 8 more articles in the media than Labcorp. MarketBeat recorded 13 mentions for Cardinal Health and 5 mentions for Labcorp. Cardinal Health's average media sentiment score of 0.83 beat Labcorp's score of 0.58 indicating that Cardinal Health is being referred to more favorably in the media.

87.2% of Cardinal Health shares are owned by institutional investors. Comparatively, 95.9% of Labcorp shares are owned by institutional investors. 0.1% of Cardinal Health shares are owned by insiders. Comparatively, 0.8% of Labcorp shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Labcorp has a net margin of 6.99% compared to Cardinal Health's net margin of 0.67%. Labcorp's return on equity of 16.74% beat Cardinal Health's return on equity.

Cardinal Health pays an annual dividend of $2.06 per share and has a dividend yield of 0.9%. Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 0.9%. Cardinal Health pays out 28.5% of its earnings in the form of a dividend. Labcorp pays out 23.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has increased its dividend for 29 consecutive years. Cardinal Health is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.